ReviewNature reviews. Disease primers2016
Calcific aortic stenosis.
Review in Nature reviews. Disease primers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 474 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Randomized Study of Inhibitory Effect of Evogliptin, the Dipeptidyl Peptidase-4 Inhibitor, on the Progression of Aortic Valve Calcification in Patients With Type 2 Diabetes Mellitus and Mild-to-moderate Aortic Stenosis
A Randomized Trial of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis
Effect and Safety of PCSK9 Inhibitors on the Progression of Mild/Middle Calcific Aortic Stenosis: A Randomized Controlled Clinical Trial
Who cites it
474 citing papers in PubMed, 3 syntheses or guidelines pooled it, 879 citations in OpenAlex.
- Sex-based differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis of randomised trials.Open heart · 2026Pooled it
- Association of lipoprotein(a) and LPA gene with calcific aortic valve disease.European journal of medical research · 2025Pooled it
- Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.Nature communications · 2024Pooled it
- Prognostic value of valve calcification and high cardiothoracic ratio for major adverse cardiovascular events and mortality in hemodialysis patients.Renal failure · 2026Article
- Orthopedic surgery changes aortic valve composition inAtherosclerosis plus · 2026Article
- Article
- Integration of multiple perspectives to understand the left ventricular pressure-volume relationship.Communications medicine · 2026Review
- Innovation and Challenges in Materials for Transcatheter Aortic Valves.Journal of cardiovascular translational research · 2026Review
- miR-138-5p Inhibits Aortic Valve Interstitial by Targeting SLC39A14 and Activating Nrf2 Signaling.Journal of biochemical and molecular toxicology · 2026Article
- Transcatheter vs surgical aortic valve replacement in young adults with chronic kidney disease: a national inpatient comparison of in-hospital outcomes.International urology and nephrology · 2026Article
- Aortic Stenosis Hyalectan Remodeling Revealed by Proteomics and Glycoproteomics.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Association of the hemoglobin-to-red cell distribution width ratio with clinical outcomes after transcatheter aortic valve implantation.Journal of geriatric cardiology : JGC · 2026Article
- AI-Derived Pericardial Effusion Volume and Long-Term Mortality After Transcatheter Aortic Valve Implantation.Journal of clinical medicine · 2026Article
- One-Click CT-Based Pipeline for Regional Quantification of Aortic Valve Fibrocalcific Degeneration.Annals of biomedical engineering · 2026Article
- Sodium-Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps-A Structured Narrative Review.Journal of clinical medicine · 2026Review
- CT-based multi-threshold calcium scoring for aortic valve assessment: comparable predictive performance across HU thresholds in a pre-TAVI cohort.The international journal of cardiovascular imaging · 2026Article
- Biatrial Inflammatory and Fibrotic Remodeling in Severe Aortic Stenosis Compared with CABG Controls.Metabolites · 2026Article
- From Valve Disease to Valve Replacement: Lipoprotein(a) Is Associated with Aortic Stenosis Severity but Not Prognosis After TAVI.Medical sciences (Basel, Switzerland) · 2026Article
- Bicuspid aortic valve stenosis is characterized by increased angiogenesis, inflammation, and a higher valvular-to-systemic calcification ratio than tricuspid aortic valve stenosis.Basic research in cardiology · 2026Article
- Long-term valve durability and clinical outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients: a systematic review and meta-analysis of randomized trials.Journal of thrombosis and thrombolysis · 2026Review
414 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed countries. It is characterized by progressive fibro-calcific remodelling and thickening of the aortic valve leaflets that, over years, evolve to cause severe obstruction to cardiac outflow. In developed countries, AS is the third-most frequent cardiovascular disease after coronary artery disease and systemic arterial hypertension, with a prevalence of 0.4% in the general population and 1.7% in the population >65 years old. Congenital abnormality (bicuspid valve) and older age are powerful risk factors for calcific AS. Metabolic syndrome and an elevated plasma level of lipoprotein(a) have also been associated with increased risk of calcific AS. The pathobiology of calcific AS is complex and involves genetic factors, lipoprotein deposition and oxidation, chronic inflammation, osteoblastic transition of cardiac valve interstitial cells and active leaflet calcification. Although no pharmacotherapy has proved to be effective in reducing the progression of AS, promising therapeutic targets include lipoprotein(a), the renin-angiotensin system, receptor activator of NF-κB ligand (RANKL; also known as TNFSF11) and ectonucleotidases. Currently, aortic valve replacement (AVR) remains the only effective treatment for severe AS. The diagnosis and staging of AS are based on the assessment of stenosis severity and left ventricular systolic function by Doppler echocardiography, and the presence of symptoms. The introduction of transcatheter AVR in the past decade has been a transformative therapeutic innovation for patients at high or prohibitive risk for surgical valve replacement, and this new technology might extend to lower-risk patients in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.